(DA) neuron activity in the ventral tegmental area (VTA) in the methylazoxymethanol acetate (MAM) animal model of schizophrenia. Methods: All experimental procedures were conducted according to NIH guidelines and were approved by University of Pittsburgh Institutional Animal Care and Use Committee. Sprague-Dawley pregnant dams were treated with MAM or saline on gestational day 17. Recordings of VTA dopamine neuron activity was performed on the male offspring at adulthood. The effects of four different drugs were evaluated: PNU282987 (full agonist), SSR180711 (partial agonist) NS1738 (type I positive allosteric modulator -PAM) and PNU120596 (PAM type II). Results: Intravenous administration of alpha7 selective ligands did not induce a major change in the firing profile of spontaneously active DA neurons when dosed during dopamine neuron recording. PNU120596 increased in the number of active DA neurons found in the VTA of normal rats, their mean firing rate and percentage of spikes in bursts. In contrast, the full agonist PNU282987 and the partial agonist SSR180711 reduced the hyperdopaminergic tone in MAM rats, with a more prominent decrease in the number of DA neurons recorded in the lateral VTA. In order to investigate the drug site of action, both PNU282987 and SSR1800711 were infused into the ventral hippocampus (vHipp) and basolateral amygdala (BLA). After vHipp infusion, the alpha7 nAChR agonists significantly decreased the number of active DA neurons in MAM rats, with no significant impact in control rats. Once more, the effects were more robust in the lateral VTA. In contrast, the same drugs when infused directly into the BLA increased the number of spontaneously active DA neurons in the VTA of normal rats, but not in the MAM model. Discussion: In summary, our results show that alpha7 nAChR positive modulators can affect midbrain dopaminergic neuronal activity in vivo in a state-dependent manner. Interestingly, alpha7 nAChR agonists counterbalanced the hyperdopaminergic state of MAM rats and this effect is partially mediated by their action in the vHipp. This effect is consistent with the potential use of alpha7 nAChR agonists for schizophrenia treatment and fits the current search for drugs able to control dopaminergic function acting in structures upstream from the dopamine receptor. The predominant inhibition of the lateral VTA points to a lower propensity to produce unwanted side effects in comparison to current employed antipsychotic agents. Our data show that drug effects can vary according to the basal level of activity of specific brain circuits and highlights the importance of using appropriated animal models to make inferences about potential therapeutic use of new neuropsychiatric drug candidates.
(DA) neuron activity in the ventral tegmental area (VTA) in the methylazoxymethanol acetate (MAM) animal model of schizophrenia. Methods: All experimental procedures were conducted according to NIH guidelines and were approved by University of Pittsburgh Institutional Animal Care and Use Committee. Sprague-Dawley pregnant dams were treated with MAM or saline on gestational day 17. Recordings of VTA dopamine neuron activity was performed on the male offspring at adulthood. The effects of four different drugs were evaluated: PNU282987 (full agonist), SSR180711 (partial agonist) NS1738 (type I positive allosteric modulator -PAM) and PNU120596 (PAM type II). Results: Intravenous administration of alpha7 selective ligands did not induce a major change in the firing profile of spontaneously active DA neurons when dosed during dopamine neuron recording. PNU120596 increased in the number of active DA neurons found in the VTA of normal rats, their mean firing rate and percentage of spikes in bursts. In contrast, the full agonist PNU282987 and the partial agonist SSR180711 reduced the hyperdopaminergic tone in MAM rats, with a more prominent decrease in the number of DA neurons recorded in the lateral VTA. In order to investigate the drug site of action, both PNU282987 and SSR1800711 were infused into the ventral hippocampus (vHipp) and basolateral amygdala (BLA). After vHipp infusion, the alpha7 nAChR agonists significantly decreased the number of active DA neurons in MAM rats, with no significant impact in control rats. Once more, the effects were more robust in the lateral VTA. In contrast, the same drugs when infused directly into the BLA increased the number of spontaneously active DA neurons in the VTA of normal rats, but not in the MAM model. Discussion: In summary, our results show that alpha7 nAChR positive modulators can affect midbrain dopaminergic neuronal activity in vivo in a state-dependent manner. Interestingly, alpha7 nAChR agonists counterbalanced the hyperdopaminergic state of MAM rats and this effect is partially mediated by their action in the vHipp. This effect is consistent with the potential use of alpha7 nAChR agonists for schizophrenia treatment and fits the current search for drugs able to control dopaminergic function acting in structures upstream from the dopamine receptor. The predominant inhibition of the lateral VTA points to a lower propensity to produce unwanted side effects in comparison to current employed antipsychotic agents. Our data show that drug effects can vary according to the basal level of activity of specific brain circuits and highlights the importance of using appropriated animal models to make inferences about potential therapeutic use of new neuropsychiatric drug candidates. Background: Patients with first-episode schizophrenia usually respond well to treatment, but relapse is frequent during the first years of the illness and may be associated with clinical deterioration A major concern in treating patients with schizophrenia is non-adherence with medication, with approximately 40% stopping within 1 year and 75% by 2 years. In addition to the impact on the illness, non-adherence creates serious social and psychological consequences. Although it is one of the potentially preventable causes of relapse, hospitalization, and poor outcome non-adherence is one of the most difficult problems to solve Aripiprazole is an atypical antipsychotic with partial agonist activity at dopamine D2 receptors and a potentially less burdensome metabolic profile compared with other atypical antipsychotics. A once-monthly, long-acting injectable (LAI) formulation, aripiprazole once-monthly 400 mg (AOM 400), is approved for the treatment of schizophrenia Methods: To assess the evolution of the functioning and attitude to medication in a sample of patients recently diagnosed of schizophrenia during one year of treatment with aripiprazole once-monthly (AoM) Schizophrenic patients from three Mental Health units in the province of Toledo (Spain) were recruited. The inclusion criteria were an age between 18 and 65 years, a diagnosis of schizophrenia (based on the ICD-10 criteria) in the last 5 years, the start of treatment with AoM in last 6 months, and 12 months of treatment with oral antipsycohtics previosly to the AoM treatment and at least one relapsed in last 4 years. A series of demographic variables were recorded and the GAF (Global Assesment Functioning) scale was used to assess function, while the Drugs Attitude Inventory (DAI) scale was used to evaluate attiudes to medication. The scales were again applied 3, 6 and 12 months after the start of treatment. Results: N=18 patients (12 males and 6 females), with a mean age of 29 years. There were 1 dropouts during the year of follow-up. The results showed an improvement in GAF score during the 12 months, manifesting from the third month (ANOVA, p<0.05). Likewise, statistically significant differences (ANOVA, p<0.05) were observed with the DAI scale for attitude to treatment; these results persisted over the year of follow-up and were manifest from the third month. Discussion: First years of evolution in schizophrenia are determinants for the evolution of the illness. The correct adherence to medication is associated with an adecuated functioning Poor adherence to treatment is a recognised is predictive of poor outcomes (relapse, aggressive behaviour, suicide, substance abuse) and increased risk of hospitalisation Guidelines suggest that long-acting antipsychotic medicines may be offered to people who would prefer such treatment or in cases where avoiding covert non-adherence to antipsychotic medication (either intentional or unintentional) is a clinical priority within the treatment plan. Background: The aim of this study is to examine the one-year outcome in a cohort of patients with a first-episode core schizophrenia diagnosis (schizophrenia, schizophreniform psychosis, schizoaffective disorder) and the use of clozapine in the non-remitted patients at one-year control. Methods: The population studied is the patients who were included with a first-episode psychosis in the TIPS project in the period 01.01. 2002-31.12.2010 and had a core schizophrenia diagnosis. We divided the patients into two groups according to their remission status at one-year follow up and compared their main characteristics. We then performed a digital search in the hospital´s journal of the non-remitted group for the words "clozapine" and "Leponex". Results: Out of the 78 patients with first-episode core schizophrenia diagnosis included in the TIPS project during the examined period, 53 were continuously psychotic at one-year follow up. The one-year remission rate for our sample was therefore 32%. All of the non-remitted patients during the first year could be eligible for clozapine, but clozapine was considered to only 3 of them (5.7 %) and only two of them were offered clozapine. The mean number of periods with antipsychotic treatment in this group was four (4). Discussion: The findings in our study show firstly a surprisingly low oneyear remission rate for first-episode schizophrenia (32 %). This is much lower than what corresponding studies of the last years show. Our results also prove the underutilization of clozapine in non-remitted patients with a
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